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Atherosclerosis-binding cassette transporter ABCG1 is greatly increased in macrophages by
cholesterol loading via the activation of the nuclear receptor LXR. Several recent studies demonstrated that
ABCG1 expression is associated with increased cholesterol efﬂux from macrophages to high-density
lipoprotein, suggesting an atheroprotective role for this protein. Our present study uncovers an as yet not
described cellular function of ABCG1. Here we demonstrate that elevated expression of human ABCG1 is
associated with apoptotic cell death in macrophages and also in other cell types. We found that
overexpression of the wild type protein results in phosphatidyl serine (PS) translocation, caspase 3
activation, and subsequent cell death, whereas neither the inactive mutant variant of ABCG1 (ABCG1K124M)
nor the ABCG2 multidrug transporter had such effect. Induction of ABCG1 expression by LXR activation in
Thp1 cells and in human monocyte-derived macrophages was accompanied by a signiﬁcant increase in the
number of apoptotic cells. Thyroxin and benzamil, previously identiﬁed inhibitors of ABCG1 function,
selectively prevented ABCG1-promoted apoptosis in transfected cells as well as in LXR-induced macrophages.
Collectively, our results suggest a causative relationship between ABCG1 function and apoptotic cell death,
and may offer new insights into the role of ABCG1 in atherogenesis.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Since the concept of apoptosis was introduced in the early 70s by
Kerr et al. [1], considerable knowledge on the physiological relevance
of this phenomenon has accumulated. In a number of physiological
processes the proper balance between cell proliferation and con-
trolled cell death regulates organ development. The progression of
atherosclerotic lesions is also determined by the balance of a series of
pro- and antiatherogenic events. In recent years, apoptosis has been
implicated as one of the key factors inﬂuencing the cellularity,
stability, and thrombogenicity of the atherosclerotic lesions (for
reviews see [2–4]).
Apoptosis in the atherosclerotic plaque can be either beneﬁcial or
harmful, depending on the cell type, the stage of the lesion, and the
context. Apoptosis of endothelial cells and smooth muscle cells favors
plaque instability [3–7], whereas macrophage apoptosis seems to be a
double edged sword. In the early lesions, decrease in the number of
macrophages is antiatherogenic as macrophage apoptosis results in a
lower level of metalloproteinase activity and reduction in collagen
breakdown, thus, increases plaque stability [2,3,8,9]. In contrast, in
advanced atherosclerotic lesions, where the clearance of apoptoticolya).
ll rights reserved.bodies by intimal phagocytes becomes limiting [2,10,11], macrophage
apoptosis is believed to promote atherogenesis. Loss of macrophages
leads to further reduction in phagocytic activity, and with a positive
feed-back mechanism results in the accumulation of non-scavenged
apoptotic bodies, which are potential sources of inﬂammatory
cytokines and tissue factors [12,13]. Thus this process leads to necrotic
core formation, complement and thrombin activation. In addition,
increased activity of metalloproteinases secreted by residual surviving
macrophages reduces the stability of the atherosclerotic lesion [2,8,9].
Inﬂammation, thrombogenicity and augmented vulnerability can
ﬁnally lead to plaque rupture. The molecular machinery regulating
macrophage apoptosis under these circumstances, however, is not
well understood.
Here we present evidence for an unexpected link between
macrophage apoptosis and the activity of an ATP-binding cassette
(ABC) transporter protein, ABCG1, highly expressed in cholesterol-
loaded macrophages. The ABCG1 membrane protein belongs to the G
subfamily of ABC transporters, the members of which are termed
‘reverse order’ half transporters. Unlike canonical ABC transporters,
ABCG proteins consist of only a single nucleotide binding domain and
a single transmembrane domain, which is localized C-terminally to
the former one. An active ABC transporter requires the presence of at
least two nucleotide binding domains and two transmembrane
domains, therefore, the half transporters have to dimerize to form a
functional unit. The ABCG1 transporter typically forms homodimers
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member of the ABCG subfamily, has also been demonstrated in our
previous study [15].
In contrast to full length ABC transporters, which normally reside
in the plasma membrane, several ABC half transporters localize to the
membranes of intracellular organelles. Not only regarding dimeriza-
tion, but also in terms of subcellular localization, ABCG1 seems to be a
Janus-faced protein because both cell surface and intracellular
expression of this transporter has been demonstrated [14,16,17].
Wang et al. proposed that a translocation of ABCG1 from the internal
membrane to the cell surface occurs in response to LXR activation [16],
although this notion was questioned by others [18]. Like most ABC
transporters, ABCG1 possesses ATPase activity, which can be stimu-
lated by putatively transported substrates [15], although direct
transport of any substrate has not been demonstrated as yet. Also,
the physiological substrates of ABCG1 remain to be identiﬁed.
Despite the growing number of studies on ABCG1, its physiological
function is still elusive. Based on its homology with the Drosophila
White gene product, which regulates the tryptophan and guanine
uptake in fruit ﬂies, the ﬁrst studies on the mammalian ABCG1
predicted its contribution to the cellular transport of tryptophan,
which is a precursor for serotonin, and suggested that the mutations
in the human ABCG1 gene may be associated with neurological
disorders [19,20]. Subsequent studies did not provide further support
for this hypothesis [21]. Recently, the most commonly accepted
concept on the ABCG1 function is that this protein plays a role in
cholesterol efﬂux in macrophages.
The involvement of ABCG1 in lipid homeostasis has been
implicated by several studies demonstrating that the expression of
ABCG1 in macrophages was induced by cholesterol load [22–24]. The
possible connection of ABCG1 with lipid metabolism was further
supported by the ﬁnding that its expression is regulated by LXR/RXR
and PPARγ [25–27], the nuclear receptor systems that typically
regulate genes controlling lipid metabolism. Direct cholesterol efﬂux
from ABCG1-overexpressing cells to HDL and other lipoprotein
particles has also been demonstrated by several studies [16,17,28–
31]. Abolition of ABCG1 expression either by RNAi knockdown or by
generation of knockout animals resulted in reduced cholesterol efﬂux
to HDL [16,29,31,32]. Surprisingly, ABCG1 was unable to induce
cellular cholesterol efﬂux to lipid-free apoA-I, the major apolipopro-
tein of HDL, to which ABCA1, another member of the ABC protein
family mediates cellular efﬂux of cholesterol [33–35]. Based on this,
ABCA1 and ABCG1 have been proposed to co-operate in the cellular
removal of cholesterol. According to this model, ABCA1 facilitates
loading of lipid-poor apoA-I with cholesterol, thus forming “nascent”
HDL, which is further lipidated by the ABCG1-dependent cholesterol
efﬂux [30,36–38].
The present work provides new insight into the possible function
of the ABCG1 transporter. Here we demonstrate a link between the
activity of ABCG1 and apoptotic cell death in macrophages and other
cell types. These observations may extend our understanding of the
formation and progression of atherosclerotic lesions.
2. Materials and methods
2.1. Expression of ABCG1 in Sf9 insect and mammalian cells
For infection of Sf9 (Spodoptera frugiperda) cells, the cDNAs of
human ABCG1 and its mutant variant (ABCG1K124M) were cloned into
recombinant baculovirus transfer vectors as described previously [15].
For transfection of mammalian cells, the entire open reading frame of
ABCG1 variants were cloned into pEGFP-N1 vectors (Becton Dickinson
Clontech) leaving a stop codon and a frame shift between ABCG1 and
eGFP sequences. The insect cell culturing and infection were carried
out as detailed in [39]. HEK293 andMDCK cells weremaintained in D-
MEM containing 10% FCS, whereas HepG2 cells were cultured in F12and D-MEM (1:1) +10% FCS. For transfection, the cells were seeded
onto eight-well Nunc Lab-Tek II Chambered Coverglass (Nalge Nunc)
at 1–3×104 per well cell density, and grown for 24 h. The cells were
transfected with the DNA constructs by using the FuGENE 6 (Roche)
reagent according to the manufacturer's instruction. The mediumwas
changed 24 h after transfection, immunoﬂuorescence and apoptosis
studies were performed 48 h post-transfection.
2.2. Isolation of monocytes and culturing macrophages
Thp-1 cells were maintained in RPMI+10% FCS medium, and
pretreated with 2 nM PMA 24 h before the induction of ABCG1
expression. Human monocytes were obtained from peripheral blood
of healthy subjects by Ficoll separation followed by CD14 immunoi-
solation. Positive selection method was applied using CD14 MicroBe-
ads andMiniMACS Separator (Miltenyi Biotec). The monocyte-derived
macrophages were cultured in D-MEM containing 10% FCS for 5 days.
The ABCG1 expression was induced in both PMA-pretreated Thp-1
cells and monocyte-derived macrophages by the addition of a
synthetic LXR agonist, T0901317 (1 μM, Alexis Biochemicals) 8 or
24 h prior to quantitative RT-PCR and cell biology studies, respectively.
2.3. RNA isolation and real time RT-PCR
To obtain total RNA, 1×106 cells were dissolved in 1 ml Trizol
(Invitrogen), and RNA was extracted according to the manufacturer's
instructions. Thepurityof theRNApreparationwascheckedbymeasuring
the absorbance ratio at 260/280nm. Samples containing 1 μgof RNAwere
used for reverse transcription, which was carried out at 42 °C for 2 h and
72 °C for 5 min using Superscript II reverse transcriptase and Random
hexamers (both from Invitrogen) according to the recommendation of the
manufacturer. cDNA obtained was used for real-time quantitative PCR
(ABI PRISM7900, AppliedBiosystems), 40 cycles of 95 °C for 10 s and60 °C
for 1 min. The sequence of the primers and probes are: ABCG1 (208+)
TCCTCTTCAAGAGGACCTTCCT (284−) CCCAATGTGCGAGGTGAT (1233+)
FAM-CATCATGAGGGACTCGGTCCTGACAC, cyclophilin: (52+) ACGGC-
GAGCCCTTGG (117−) TTTCTGCTGTCTTTGGGACCT (69+) FAM-
CGCGTCTCCTTTGAGCTGTTTGCA. The comparative Ct method was used
to quantify transcript levels and to normalize for cyclophilin expression.
2.4. Generation of monoclonal antibodies and Western blot analysis
Mice previously immunized with a GST-fused N-terminal domain
of ABCG1, and producing ABCG1-speciﬁc sera as demonstrated in [15],
were sacriﬁced and hybridoma cells were generated at the EMBL
Antibody Core Facility (Monterotondo, Italy). The ELISA-positive
hybridoma cells were cloned by limiting dilution and their super-
natants were tested byWestern blot analysis using ABCG1-containing
Sf9 membrane preparations. Immunoblotting was performed as
previously described [39]. The clones producing high level of antibody
were expanded and their supernatants were enriched in the
antibodies by step-wise serum deprivation. The supernatants were
further concentrated by centrifugal ultraﬁltering and the monoclonal
antibodies were isotyped. Their selectivity was tested by immuno-
blotting using Sf9 membranes containing ABCG1, ABCG4, ABCG2,
ABCG5, or ABCG5. Subsequent Western blot analyses and immuno-
ﬂuorescence studies were performed by using 6G1/7, a highly
sensitive and speciﬁc, IgG1 isotype anti-ABCG1 monoclonal antibody.
2.5. Immunoﬂuorescence staining
For immunoﬂuorescence studies, the cells were gently washed
with Dulbecco's modiﬁed PBS (DPBS), and ﬁxed with 4% paraformal-
dehyde in DPBS for 5 min at room temperature. After 5 washes with
DPBS, the samples were further ﬁxed and permeabilized in pre-chilled
methanol for 5 min at −20 °C. The cells were then blocked for 1 h at
Fig. 1. Accelerated cell death caused by functional expression of ABCG1 in Sf9 cells. The
wild type ABCG1 (ﬁlled square), its inactive mutant variant ABCG1KM (open circle),
ABCG2 (ﬁlled up triangle), and β-galactosidase (open down triangle) were expressed in
Sf9 heterologous expression system. The fraction of living cells was determined by
Trypan-blue counterstaining at different time points after infection carried out under
identical conditions (108 PFU virus per 107 Sf9 cells). Cells expressing the functional
ABCG1 exhibited reduced viability as compared to cells expressing ABCG1KM, ABCG2, or
β-gal. Results are presented as mean±s.e.m. (n=4). Asterisks indicate signiﬁcant
difference between the viabilities of cells expressing wtABCG1 or ABCG1KM (pb0.05).
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albumin, 1% ﬁsh gelatin, 0.1% Triton-X 100, and 5% goat serum
(blocking buffer). The samples were then incubated for 1 h at room
temperature with 6G1/7, anti-ABCG1 antibody, diluted 100x in
blocking buffer. After washing with DPBS, the cells were incubated
for 1 h at room temperature with Alexa Fluor 488-conjugated goat
anti-mouse IgG (H+L) (Molecular Probes), diluted 250× in blocking
buffer. For isotype control, mouse IgG1 (Sigma) and Alexa Fluor 488-
conjugated goat anti-mouse IgG were used. The green ﬂuorescence of
stained samples was studied by an Olympus FV500-IX confocal laser
scanning microscope using a UPLAPO 40× (0.85) dry or a PLAPO 60×
(1.4) oil immersion objective (Olympus) at 488 nm excitation.
2.6. Cell death and apoptosis studies
For assessment of Sf9 cell death, the insect cells were infected with
recombinant baculoviruses containing the sequences of the human
ABCG1, ABCG1KM, ABCG2, or β-galactosidase under identical circum-
stances (108 PFU virus per 107 cells) [15,39]. The fraction of living cells
was determined 24, 36, 48, 72 and 96 h after infection by using
Trypan-blue (Sigma) counterstaining.
To study apoptosis in mammalian cells, the cells were incubated
with Alexa Fluor 488-conjugated Annexin V (Molecular Probes) in
1:20 dilution in Annexin binding buffer (10 mM Hepes, 140 mM NaCl,
2.5 mM CaCl2, pH: 7.4) containing 2 μM propidium iodide for 3 min.
When indicated, the cells were preincubated with 100 μM thyroxin or
50 μM benzamil 24 h before apoptosis studies. In control experiments,
apoptosis was induced by the addition of 2 nM staurosporine 5 h prior
to studies. For combined PS translocation and caspase 3 studies, the
cells were ﬁrst incubatedwith a ﬂuorogenic caspase 3 substrate,10 μM
PhiPhiLuxG2D2 (Calbiochem)+10% FCS (ﬁnal conc.: 9 μM) for 20 min,
washed twice and labeled with Alexa Fluor 488-conjugated Annexin V
as described above. For combined PS translocation and immunoﬂuor-
escence studies, the cells were ﬁrst labeled with Alexa Fluor 488-
conjugated Annexin V, washed, ﬁxed, and immunostained as
described above using Alexa Fluor 647-conjugated secondary anti-
body. The stained samples were studied with the confocal microscope
speciﬁed above. The green, red, and deep red ﬂuorescence were
acquired between 505–525, 560–600 nm and above 650 nm, using
488, 543, and 633 nm excitations, respectively.
For quantitative evaluation of Annexin V binding, the labeled cells
were counted in the ﬂuorescence image, whereas the total cell
number was determined in the corresponding DIC image. The fraction
of Annexin V-labeled cells (% of total) was determined in 6–8 ﬁelds of
view in several independent experiments (nN3). For statistical
analyses, unpaired, 2-tailed, Student's t-test was used. Results are
expressed as mean±s.e.m.
3. Results
In our previous work, we have biochemically characterized the
ABCG1 transporter by using a heterologous baculovirus Sf9 insect cell
system. In this transient expression system, transfection of the insect
cells with baculovirus ultimately results in cell death. However, we
have observed that the fraction of living cells in cultures expressing
the wild type ABCG1 (wtABCG1) was signiﬁcantly lower than in
control cultures transduced with either β-galactosidase (β-gal),
ABCG2, or the inactive, catalytic site mutant variant of ABCG1
(ABCG1KM), even though the infection procedure were carried out
under identical circumstances (108 PFU virus per 107 Sf9 cells) (Fig. 1).
The proteins were expressed at similar high levels 72 h after
transduction as observed by Coomassie staining or by Western
blotting for ABCG1 and ABCG1KM (data not shown). The half life
times determined from the kinetic analysis shown in Fig.1, were 40.5±
1.2 h for cells transduced with the wild type ABCG1, and around 60 h
for cells expressing ABCG1KM, ABCG2, or β-gal. Accordingly, cellsexpressing wtABCG1 exhibited low accumulation of ﬂuorescent
viability markers, MitoTracker and calcein, as compared to their
accumulation in cells expressing β-gal, ABCG2, or ABCG1KM (data not
shown).
Previously, we demonstrated that the membrane cholesterol
content substantially inﬂuences the activity of ABCG2 multidrug
transporter [40]. Either cholesterol depletion or expression in
cholesterol-poor Sf9 cell membrane results in reduced activity of
ABCG2. Such a cholesterol-dependence has not been demonstrated for
the activity of ABCG1. The signiﬁcant difference seen between the
viability of Sf9 cells expressing wtABCG1 or ABCG1KM indicates that
ABCG1 remains active in the cholesterol-poor Sf9 membrane.
To explore whether the ABCG1-induced cell death can also be seen
in mammalian cells, we expressed ABCG1 and its inactive variant
(ABCG1KM) in various cell lines (HEK-293, HepG2, COS-7, and MDCK
cells). Mammalian cells transiently transfected with ABCG1 or
ABCG1KM were immunostained with our monoclonal antibody
speciﬁc for ABCG1 (6G1/7), and the morphology of the transfected
cells was studied by confocal microscopy. As documented in Fig. 2,
expression of wtABCG1 induced changes in cell shape with character-
istic ‘rounding up’ and detachment, whereas cells expressing ABCG1KM
exhibited normal cell morphology. In cultures transfected with
wtABCG1, a substantial amount of cell debris, stained positively with
the anti-ABCG1 monoclonal antibody, was also observed.
For subsequent functional studies we attempted to generate stable
cell lines expressing the variants of ABCG1. Since the vectors used for
transient transfection contained neo-resistance, the HEK-293 cells
transfected with ABCG1 or ABCG1KM were subsequently selected with
G418 for 10–14 days. Several attempts of generating a stable cell line
expressing the wild type ABCG1 have failed, while we were able to
obtain cells stably expressing the ABCG1KM mutant regularly.
Furthermore, MDCK cells were transduced by retroviruses containing
the ABCG1 and ABCG1KM sequences. The expression was frequently
checked by Western blot analysis. After a short transient expression
the cells lost the wild type protein, whereas cells transduced with the
ABCG1KM variant stably expressed the protein (data not shown). These
results are consistent with the observations of accelerated cell
degradation seen in the ABCG1-transfected Sf9 cells, and implicated
that the expression of the wtABCG1 also causes cell death in
mammalian cells.
Since the morphological alterations observed in the ABCG1-
expressing mammalian cells were indicative of apoptosis, next we
examined several apoptotic markers in HEK-293 and HepG2 cells
Fig. 2.Morphology changes associated with the functional expression of ABCG1 in various mammalian cells. HEK-293 (A, D), HepG2 (B, E) andMDCK (C, F) cells were transfected with
the wild type ABCG1 (A–C) and the inactive mutant ABCG1KM (D–F). The cultures were immunostained with 6G1/7, an ABCG1-speciﬁc monoclonal antibody 48 h after transfection.
Immunoﬂuorescence was studied by confocal microscopy. Cells expressing the wild type ABCG1 protein were loosely attached and exhibited a ‘rounded up’ morphology, which is
typical for apoptotic cells, whereas cells expressing ABCG1KM exhibited normal cell morphology. The white bars indicate 10 μm.
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binding was used tomonitor the early apoptotic event of phosphatidyl
serine (PS) translocation, while the activity of caspase 3, one of the key
enzymes of apoptosis, was visualized by using the cell-permeable,
ﬂuorogenic caspase 3 substrate, PhiPhiLuxG2D2.
We found that the cultures transfected with wtABCG1 contained a
large number of cells exhibiting Annexin V binding and elevated
caspase 3 activity (Fig. 3A–C). The two apoptotic markers showed
mostly overlapping patterns. In contrast, hardly any labeling for PS
translocation and caspase 3 activity was seen in cultures transfected
with ABCG1KM (Fig. 3D–G). The protein expression was veriﬁed by
Western blotting in both cases (data not shown). It is important toFig. 3. Apoptotic markers in cell cultures transfected with ABCG1 or ABCGKM. Phosphatidyl se
transiently transfected with the wild type ABCG1 (A–C) or its inactive variant, ABCG1KM (D–G
shown. PS exposure was visualized by the cell surface labeling of Annexin V conjugated
PhiPhiLuxG2D2, a cell-permeable caspase 3 substrate, which produces a red ﬂuorescent produ
of cells were positively labeled for both PS translocation and caspase 3 activation in cultu
ABCG1KM-transfected cultures. The DIC image is to show the presence of the cells in the nenote that despite caspase 3 and Annexin V positivity observed in the
wtABCG1-expressing cells, membrane blebbing, another character-
istic feature of apoptotic cells, or the condensation of the nuclei, as
visualized by ﬂuorescent nuclear staining, was not typically observed
in these cells.
To investigate whether PS translocation is functionally associated
with ABCG1 expression, Annexin V binding and ABCG1 expression
were simultaneously investigated in HEK-293 and HepG2 cells
transfected with wtABCG1 or ABCG1KM. Close correlation between
Annexin V binding and protein expression was observed in cultures
transfected with the wild type protein (Fig. 4A–C). In contrast, no
labeling with Annexin V was seen in cultures transfected withrine (PS) translocation and caspase 3 activity were assessed in HEK-293 and HepG2 cell
) 48 h after transfection. Representative experiments performed with HEK-293 cells are
with a green ﬂuorophore (A, D), whereas the activity of caspase 3 was assessed by
ct upon cleavage (B, E). Merged images are shown on the right (C, F). Substantial portion
res transfected with the wild type protein, whereas hardly any staining was seen in
gatively stained sample. The white bars indicate 30 μm.
Fig. 4. Simultaneous assessment of phosphatidyl serine translocation and ABCG1 expression in cells cultures transfected with ABCG1 or ABCGKM. HEK-293 and HepG2 cells
transfected with ABCG1 (A–C) or ABCG1KM (D–F) were labeled with Alexa Fluor 488-conjugated Annexin V 48 h after transfection. The samples were subsequently ﬁxed and
immunostained with the ABCG1-speciﬁc monoclonal antibody, 6G1/7. Results obtained with HepG2 cells are shown. Annexin V binding (A, D) is depicted on the left, middle panels
show the immunostaining (B, E), whereas merged images are shown on the right (C, F). In the ABCG1-transfected cultures, Annexin V binding was observed only in cells expressing
ABCG1. In contrast, no labeling with Annexin V was seen in cultures transfected with ABCG1KM, although the protein was expressed and localized normally. Similar results were
obtained with HEK-293 cells. The white bars indicate 30 μm. Insets show a representative cell from the same ﬁeld at higher magniﬁcation; bars: 5 μm.
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the mutant protein was expressed both on the cell surface and within
intracellular compartments, similar to the wild type protein. It is
important to note that apoptotic signs were only observed in cells
expressing the ABCG1 protein (see Discussion).
The observation that the expression of the wild type ABCG1
resulted in morphological and functional alterations typical for
apoptosis, whereas the inactive, catalytic sitemutant variant exhibited
no sign of apoptosis, suggested that the apoptotic events are related to
the activity of the transporter. For exploring this question, in the
subsequent experiments we employed thyroxin and benzamil, which
were identiﬁed as efﬁcient inhibitors of the ABCG1 ATPase activity inFig. 5. Inhibition of phosphatidyl serine translocation in ABCG1-expressing cells with the inh
and HepG2 (B) cell cultures transfected with the empty vector, ABCG1 or ABCG1KM. For quan
image, the total cell number was determined in the corresponding DIC image. Results are ex
3000 cells were analyzed for each column in at least three independent experiments. Results
were 29.2±3.5 and 12.1±1.2, respectively. Signiﬁcantly elevated number of apoptotic cells wa
with the vector or ABCG1KM (black bars) (⁎, pb0.001 by Student's t-test). Preincubation with
benzamil (benz, hatched bars), completely prevented PS translocation in the ABCG1-express
binding in cells transfected with the empty vector or ABCG1KM, neither in cultures, in whicprevious studies [15]. The quantitative analysis of Annexin V binding
in ABCG1-transfected HEK-293 and HepG2 cells shown in Fig. 5
veriﬁed that the cultures transfected with the wild type ABCG1
contain signiﬁcantly more Annexin V positive cells as compared to
cultures transfected with the empty vector. However, preincubation of
the cells either with thyroxin or benzamil completely blocked the
ABCG1-induced apoptosis. Annexin V binding in ABCG1KM-trans-
fected cells was not different from the vector control, and was not
affected by thyroxin or benzamil pretreatment.
For a comparison of the fraction of Annexin V positive cells in HEK-
293 and HepG2 cell cultures, the values ought to be corrected by the
transfection efﬁcacy, whichwas about 30% in HEK-293 cells and 15% inibitors of ABCG1 function. The fraction of apoptotic cells was determined in HEK-293 (A)
titative analysis, the Annexin V-labeled cells were counted in the confocal ﬂuorescence
pressed as positively stained cells as percentage of total cell number. Between 1000 and
are presented as mean±s.e.m. The transfection efﬁciency for HEK-293 and HepG2 cells
s seen in cultures transfected with wild type ABCG1 as compared to cultures transfected
the previously identiﬁed inhibitors of ABCG1 function, thyroxin (thyr, white bars) and
ing cells (⁎⁎, pb0.001 by Student's t-test). These compounds had no effect on Annexin V
h apoptosis was induced by staurosporine (STS) or TNFα (see insets).
Fig. 6. Induction of ABCG1 expression in Thp-1 cells by LXR agonist; assessment of apoptosis in the LXR-induced Thp-1 cells. PMA-pretreated Thp-1 cells were subjected to 1 μM
T0901317, an LXR agonist, and expression of endogenous ABCG1 expressionwas detected byWestern blotting (A) and quantitative PCR (B). Western blot analysis was performedwith
total cell lysates (50 μg protein) using 6G1/7, ABCG1-speciﬁc antibody. As a positive control, HEK-293 cells transfected with ABCG1 (5 μg protein) was used. Considerable elevation in
the ABCG1 expression was observed at both mRNA and protein levels in response to the LXR agonist. Quantitative Annexin V binding experiments were performed with PMA-
pretreated Thp-1 cells (C) as described in detail in the legend of Fig. 5. In parallel with the induction of ABCG1 expression, T0901317 signiﬁcantly increased the number of apoptotic
cells (black bars). This elevation was completely inhibited by the pretreatment with 100 μM thyroxin (thyr), a blocker of ABCG1 function (C, white bars), without any effect on the
expression level of the transporter (B, white bar). Results are expressed as mean±s.e.m. Asterisks indicate signiﬁcant differences: ⁎, when compared with vehicle control; ⁎⁎, when
compared with cells not-pretreated with thyroxin by Student's t-test (pb0.005). n.d.: not detected.
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exhibited Annexin V labeling at the examined time point, i.e., 48 h
after transfection. In order to demonstrate the relative speciﬁcity of
the effect of thyroxin and benzamil on ABCG1-induced apoptosis, in
parallel experiments apoptosis was induced by staurosporine both inFig. 7. Parallel induction of ABCG1 expression and apoptosis in human monocyte-derived m
derivedmacrophageswere obtained from peripheral blood by CD14 immunoisolation. After 5
of ABCG1 was measured by quantitative PCR (A). In parallel the fraction of apoptotic cells w
apoptotic cells were signiﬁcantly increased in response to LXR activation (black bars). Preincu
prevented PS translocation in the LXR-ligand-induced cells, without any effect on ABCG1 e
binding, in control experiments apoptosis was induced in the monocyte-derived macroph
binding in the STS-induced apoptotic cells. ABCG1 expression was not induced by stauros
differences: ⁎, when compared with vehicle control; ⁎⁎, when compared with non-treatedHEK-293 and HepG2 cells. As shown in Fig. 5, the fraction of Annexin
positive cells in the staurosporine-treated cultures was not reduced by
the ABCG1 inhibitors. Similarly, Annexin V binding in TNFα-induced
HepG2 cells was not affected by the pretreatment with thyroxin or
benzamil.acrophages and inhibition of apoptosis with the ABCG1 inhibitors. Human monocyte-
days of culturing, the cells were incubatedwith 1 μMT0901317, and the expression level
as determined by Annexin V binding (B). Both ABCG1 expression level and number of
bationwith 100 μM thyroxin (thyr, white bars) or 50 μM benzamil (benz, hatched bars),
xpression. To exclude a non-speciﬁc effect of thyroxin and benzamil on the Annexin V
ages by staurosporine (STS) pretreatment. These compounds did not block Annexin V
porine (A). Results are expressed as mean±s.e.m (n=4). Asterisks indicate signiﬁcant
cells by Student's t-test (pb0.001).
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a consequence of forced expression of the transporter, or the
phenomenon also occurs in cell types that endogenously express
ABCG1, we investigated Annexin V binding in PMA-pretreated human
Thp-1 cells (a macrophage model system), and in isolated human
monocyte-derived macrophages. The endogenous ABCG1 expression
in these cell types was induced by T0901317, a known activator of LXR,
the nuclear receptor that regulates ABCG1 gene [26,27].
As shown in Fig. 6, in Thp-1 cells the expression level of ABCG1was
studied by both quantitative PCR andWestern blotting and, in parallel,
the fraction of apoptotic cells was determined by Annexin V binding.
As expected, a marked induction in the ABCG1 expressionwas seen in
response to LXR activation (Fig. 6A, B). In parallel, hardly any Annexin
V positivity was seen in the control cells, which were treated with the
vehicle only, whereas substantial Annexin V labeling was observed in
the LXR-induced cultures (Fig. 6C). Similar to that seen in the ABCG1-
transfected cell lines, preincubation with thyroxin prevented Annexin
V labeling in the LXR-ligand-induced Thp-1 cells.
In similar experiments, carried out with monocyte-derived human
macrophages, a substantial induction of ABCG1 expression and a
subsequent elevation of the fraction of apoptotic cells were seen in
response to LXR agonist (Fig. 7). Preincubation with thyroxin and
benzamil completely blocked Annexin V labeling in the LXR-ligand-
induced macrophages without affecting the ABCG1 expression. These
observations indicate that the PS translocation in the LXR-induced
macrophages depends on the functional presence of ABCG1 protein.
To exclude a non-speciﬁc effect of thyroxin and benzamil on Annexin
V binding, apoptosis was also induced by staurosporine in these cells.
As shown in Fig. 7, the expression of ABCG1 was not elevated by
staurosporine, and the marked Annexin V binding observed in the
staurosporine-induced cells was not reduced by thyroxin or benzamil
pretreatment (rather a small increase was detected).
4. Discussion
In order to explore the functional role of the human ABCG1
membrane transporter protein, in the present experiments we
explored the effects of ABCG1 expression in numerous cell types,
including human macrophages involved in atherosclerosis develop-
ment. Previous studies suggested that overexpression of ABCG1
causes an increase in cholesterol efﬂux from cells to HDL and other
lipid acceptors [16,17,28–31]. In addition to such a possible role, our
present experiments suggest another cellular function for ABCG1, and
may offer new insights into the function of this transporter protein.
Here we demonstrate that ABCG1 functionally contributes to
apoptotic events in various cell types, the function of the over-
expressed protein is closely connected to cell death, activation of
caspase 3, and PS translocation. We show that physiological ABCG1
expression, induced by the addition of a synthetic LXR agonist in
monocyte-derived macrophages or PMA-treated Thp-1 cells, also
results in a substantial increase in phosphatidyl serine surface
exposure. In all cases the function of ABCG1 is required to evoke
these apoptotic signs.
Several previous studies demonstrated an induction of ABCG1
expression in macrophages in response to cholesterol loading
[22,23,41], whereas other studies showed PS translocation in macro-
phages induced by cholesterol [42,43]. However, the causative
connection between ABCG1 and apoptotic events was documented
in our present study by the effects of ABCG1 inhibitors on PS exposure.
In addition, the fact that the ABCG1-transfected cells exhibited PS
surface exposure, whereas this was not observed in cells transfected
with the inactive ABCG1 variant (ABCG1KM), clearly indicates an
association between the PS translocation and the transport activity of
ABCG1.
A distant relative of ABCG1 in the ABC protein family, MDR3
(ABCB4) is known as a phosphatidyl choline (PC) ﬂoppase, translocat-ing PC from the inner membrane leaﬂet to the outer leaﬂet. Based on
this homology, we may hypothesize that ABCG1 acts as a PS
translocator. However, PS surface exposure in the ABCG1-expressing
cells is most likely not a consequence of direct ﬂoppase activity, but a
component of a concerted apoptotic process, since caspase 3
activation as well as accelerated cell death were observed in cells
expressing the wild type ABCG1. None of these apoptotic events was
seen in cells expressing the inactive, catalytic site mutant variant of
ABCG1 (ABCG1KM), although the expression level and the subcellular
localization of the mutant form was similar to those of the wild type
protein. Therefore, our results imply a functional association between
macrophage apoptosis and ABCG1 transport activity.
Numerous studies reported collateral sensitivity to certain com-
pounds along with the overexpression of ABCB1 (MDR1/Pgp) or
ABCC1 (MRP1). These drugs exempliﬁed by gemcitabine, cytosine
arabinoside, arsenic trioxide, and NSC73306 for ABCB1 [44–47], as
well as verapamil, its derivative, NMeOHI2, cytosine arabinoside,
melphalan, apigenin, and buthionine sulphoximine for ABCC1 [48–
51]. Although the mechanism behind this collateral sensitivity is still
elusive, it has been suggested that at least in ABCC1-expressing cells
the decreased glutathione level content and the subsequent oxidative
stress account for the hypersensitivity to drugs causing further
reduction in glutathione content. Since in our study no exogenous
drug was added to the cells, some endogenous component(s) can be
responsible for the ABCG1-promoted cell death.
There are several factors that are known to induce apoptosis in
macrophages. These include ATP depletion, binding of death
receptors ligands, growth factor withdrawal, high concentration of
oxidized LDL, oxysterols, and intracellular accumulation of unester-
iﬁed or “free” cholesterol [2,42,43,52]. In addition to their apoptotic
effect, these agents are also known to induce ABCG1 expression in
macrophages [22,23,27,41,53], which is in accordance with our
present results.
Regarding the ABCG1-dependent apoptosis found in this study,
several possibilities can be excluded from the list of the aforemen-
tioned pro-apoptotic factors. ATP depletion cannot account for the
ABCG1-dependent apoptosis, since overexpression of a closely related
ABC transporter, ABCG2, which possesses higher ATPase activity, does
not result in PS translocation, caspase 3 activation, and subsequent cell
death (see Fig. 1). The involvement of death receptors is also unlikely,
since TNFα-induced apoptosis was not blocked by the inhibitors of
ABCG1.
A possible explanation for the mechanism of ABCG1-dependent
apoptosis could be that the transporter may act as an export pump,
and mediate the excretion of certain cytotoxic compounds to the
media, which cause apoptosis in the adjacent cells. Recently, it has
been suggested that 7β-hydroxycholesterol or 7-ketocholesterol is
expelled from cells by ABCG1 [54,55]. In order to explore this
possibility, we examined whether the apoptotic effect of ABCG1 is
restricted to the cell that expresses the transporter or a paracrin effect
can be seen on the adjacent cells. As shown in Fig. 4B, PS translocation
was observed solely in ABCG1-expressing cells, and no signs of
apoptosis can be seen in the neighboring cells. In addition, we co-
cultured GFP-expressing cells with ABCG1-transfected cells, but no
apoptotic GFP-expressing cells adjacent to the ABCG1-expressing cells
were seen (data not shown). Based on these experimental observa-
tions the paracrin model seems to be unlikely.
As mentioned above, intracellular accumulation of unesteriﬁed or
free cholesterol is one of the apoptotic inducers in lesional macro-
phages. It has been demonstrated that free cholesterol-induced
apoptosis is a multifactorial process, which involves ER stress caused
by free cholesterol trafﬁcking to ER, which, in turn, results in unfolded
protein response (UPR), and activation of the C/EBP homologous
protein (CHOP) [56–58]. Other cellular events that greatly inﬂuence
free cholesterol-induced macrophage apoptosis include activation of
c-Jun N-terminal kinase (JNK), biding of scavenger receptor A (SRA)
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phospholipase A2 (iPLA2β) [57–60]. The requirement of cholesterol
trafﬁcking to the ER is demonstrated by the inhibitory effect of
selective blockers of cholesterol trafﬁcking [56,61], and by the reduced
macrophage apoptosis in advanced lesion inmicewith a heterozygous
mutation in the cholesterol-trafﬁcking protein Niemann-Pick C1 [62].
Given that ABCG1 is likely involved in cholesterol transport and it
exhibits both cell surface and intracellular expression [14,16,17,36,63],
we can speculate that elevated expression of this transporter results in
ER stress, which in turn, leads to apoptosis. This hypothesis presumes
that the transport activity of ABCG1 surpasses the cholesterol
esteriﬁcation capacity of the cell, which results in accumulation of
free cholesterol in the ER. However, this speculativemodel needs to be
investigated and experimentally justiﬁed.
At present the most widely accepted concept for the physiological
function of ABCG1 is that this transporter expels cholesterol from
macrophages and other cell types to HDL. It is a plausible explanation
for the ABCG1-induced apoptosis that the observed cell death is a
consequence of the cholesterol efﬂux associated with the functional
ABCG1, since neither the ABCG1KM- nor the ABCG2-expressing cells
exhibited this phenotype. Although it was previously suggested that
ABCG2 stimulates cellular efﬂux of sterols including cholesterol [64],
this hypothesis was based on the observation that sterols stimulate
the ATPase activity of ABCG2 expressed in bacterial membrane lacking
cholesterol. To our recent understanding ABCG2 does not expel
cholesterol but its ATPase activity is allosterically stimulated by
cholesterol [40]. Nevertheless, cholesterol depletion itself did not
signiﬁcantly increase the number of apoptotic cells in HEK-293 culture
pretreatment with 4 mM cyclodextrin for 30 min, despite the fact that
about 25% decrease in total cholesterol content was achievedwith this
treatment (data not shown).
The hypothesis that ABCG1 extrudes cellular cholesterol to HDL
is based on numerous in vitro and in vivo studies demonstrating
cellular cholesterol efﬂux in connection with ABCG1 expression
[14,16,17,28–32,36,55]. However, the speciﬁcity of this transport
process is questioned by the fact that similar ABCG1-mediated
cholesterol efﬂux was seen to various lipid acceptors, such as LDL,
PC vesicles, PC/ApoA-I discs, even BSA and cyclodextrin [14,16,31,36].
The observation that Ldr −/− mice transplanted with ABCG1 −/−
bone marrow exhibited reduced cholesterol level in lipoproteins
other than HDL [55], makes the speciﬁc role of HDL in ABCG-
mediated cholesterol efﬂux even more tentative. Our recent ﬁnding,
that ABCG1 promotes macrophage apoptosis, provides an alternative
explanation for the non-speciﬁc cholesterol efﬂux in connection
with ABCG1 expression. Our observation suggests that cholesterol
efﬂux can be a consequence of cell death induced by ABCG1. This
model is also consistent with the suggested protective role of ABCG1
in the atherogenesis [38,65].
Another concern that adds complexity to the issue of ABCG1-
dependent apoptosis is that two recent studies suggested that
ABCG1 diminishes the apoptotic effect of 7β-hydroxycholesterol or
7-ketocholesterol on macrophages [54,55]. This apparent contra-
diction can be resolved if we take into consideration that these
studies demonstrated increased susceptibility to exogenously added
cytotoxic compounds when ABCG1 was defective (either by using an
inactive mutant form, or cells from ABCG1 knockout animals),
whereas our study is based on endogenous transport activity of
ABCG1. Since the externally added oxysterols at low concentrations
can act as competitive inhibitors of the endogenous substrate(s),
addition of these compounds can result in a decreased cell death in
cells possessing active ABCG1. In accordance with this concept, only
a slight and transient change in the dose–response relations was
seen in connection with ABCG1 in the aforementioned studies
[54,55]. An alternative explanation for the notion that ABCG1 can
act both as an inducer and inhibitor of macrophage apoptosis is that
the transporter may play different roles, depending on itssubcellular localization. When the transporter is located in the
plasma membrane, it can expel cytotoxic compounds from the cell,
whereas it can stimulate apoptosis, when located in the internal
membranes, e.g., can induce an ER stress.
Whether ABCG1-dependent apoptosis of macrophages has a
physiological and clinical relevance, our ﬁndings should be
evaluated in the context of studies in animal model systems of
atherosclerosis. These studies demonstrated an inverse relationship
between macrophage apoptosis and the early lesion area, and
concluded that macrophage apoptosis is physiologically beneﬁcial in
the early atherosclerotic lesions [2,3,66–69]. In contrast, loss of
macrophages becomes detrimental in the advanced lesions, where
phagocytic activity becomes limiting [2,3,10,11]. With respect to the
role of ABCG1 in atherogenesis, recent in vivo studies have led to
contradicting results, demonstrating either an increase or a reduc-
tion in lesion size in mice transplanted with ABCG1-deﬁcient bone
marrow [70–75]. It has been hypothesized by L. K. Curtiss in an
editorial [76] that the different degree of hyperlipidemia achieved in
the recipient animals, and consequently the different progression
rate of atherosclerosis can account for these conﬂicting results. Our
recent ﬁnding, the phenomenon of ABCG1-promoted apoptosis, is in
accordance with this hypothesis, and can reconcile the disparate
results of ABCG1 transplantation studies. Since macrophage apop-
tosis can be both atherogenic and atheroprotective, ABCG1, which
may be involved in the apoptotic processes, can also have a dual
role in the pathogenesis of atherosclerosis, depending on the
progression of atherosclerosis.
Although the above discussion focused on macrophage apoptosis,
the ABCG1-promoted apoptosis described here might have a role in
other cells types as well, in which this transporter is expressed in an
inducible manner. These include vascular endothelial cells, astrocytes,
microglia, and neuronal cells [28,63,77–81]. Given that apoptotic cell
death has a crucial role in neuroprotection and normal vascular
function, it is an intriguing possibility that ABCG1 expression and
function contributes to apoptotic processes in these tissues.
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